Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf Van Reet, who retires.
Clay has been a non-executive director of ThromboGenics since 2011 when he replaced his father, Landon Clay.
He said: “I Am very honoured to be appointed as chairman of the board of ThromboGenics at a time when the company is starting to make excellent progress with its exciting pipeline of four novel therapies for treating diabetic eye disease.”
Clay is also vice-president of East Hill Management, a US-based investment company and serves as chairman and CEO of Golden Queen Mining and as a director of the Clay Mathematics Institute.
Patrik De Haes, chief executive officer of ThromboGenics, said: “I am delighted that Thomas has agreed to take on the role of chairman, his rich experience and deep understanding of ThromboGenics and life sciences in general will be invaluable for the company in achieving its objectives going forward.”